America is in the throes of an obesity "epidemic," but the famously wary FDA hasn't approved a new diet pill in more than a decade. That may change with Orexigen Therapeutics' debut drug, Contrave, which an FDA panel recommended for approval Tuesday. The FDA itself still has to sign off on the drug, but tends to follow the panel's recommendations. How does Contrave work, and will it be the silver bullet for America's weight problem? (Watch a Fox Business discussion about skepticism over Contrave)
What's Contrave's secret?
It combines two existing drugs: Bupropion (aka Wellbutrin), the popular antidepressant and smoking-cessation medication, and naltrexone, used to counter alcohol addiction. This combination apparently boosts metabolism while decreasing appetite to help people lose weight.
Are the side effects bad?
Since Contrave contains two long-established drugs, the panel decided the risks are pretty well understood, and clinical trials suggest that the negative effects of combining the two are pretty modest: A slight increase in blood pressure and pulse, which in theory could contribute to heart attacks or strokes. Bupropion can also cause seizures. The FDA panel, while positive, did recommend that Orexigen conduct longer, wider studies after Contrave is approved.
How effective is it?
Slightly better than the traditional diet strategy: Eating healthier and exercising more. The trial participants who received Contrave knocked an average of 4.2 percentage points more off their weight than those taking placebos. That's less than the FDA likes, but the pill passed muster because at least 35 percent of Contrave-takers lost 5 percent or more of their weight during the year-long trial. "I think [Orexigen] made it by the hair of their chinny chin chin," says Melanie G. Coffin, the patient representative on the panel. "It's sad to see that that is as far as they could go."
What other diet pills are out there?
The only prescription diet pill on the U.S. market is the rarely prescribed Xenical, which can cause liver problems, gas, and uncontrolled bowel movements. The entire U.S. weight-loss drug market is only about $382 million annually, according to IMS Health. If Contrave is approved (and is tolerated as well as expected), it could reach sales of $1.2 billion by 2018, forecasts BioMedTracker.
Given the obesity crisis, why are there so few pills?
The FDA has typically deemed diet pills too risky. Merida, one that was approved (in 1997), was just pulled from the shelves in October after studies showed it increased the risk of strokes and heart attacks. Anti-obesity groups say the FDA has been too cautious, or set the bar too high. "This panel has voted against every obesity treatment that has come before it this year," anti-obesity advocate Theodore K. Kyle told the panel. "I ask you to take the disease seriously and take the benefits of treatment seriously."
Will Contrave revolutionize weight-loss?
Not necessarily. It will be one of the "very few options" available to those for whom weight loss is "not just a matter of willpower," says Kate James in Gather.com. "The main advice is diet and exercise, which is great and can help. However, there are obviously some people who need additional help." Financially, Contrave will undoubtedly "be wildly successful, at least at first," says University of Florida pharmacy professor Paul Doering. Will it work as a diet pill? Time will tell, but "I'm going to let somebody else be the first to take it."
THE WEEK'S AUDIOPHILE PODCASTS: LISTEN SMARTER
- 10 things you need to know today: October 30, 2014
- Beware of Splenda: The backlash against artificial sugars
- 6 things the happiest families all have in common
- For Democrats, the right lesson from 2014 is to be more liberal
- 43 TV shows to watch in 2014
- Sorry, we will not all be having sex with robots in the future
- How to live a long life, according to science
- How to be the most productive person in your office — and still get home by 5:30 p.m.
- Stop making fun of philosophy and read some philosophy
- 13 Urban Outfitters controversies
Subscribe to the Week